EXCELLYSE I

EXCELLYSE I
Regulatory status
CE IVD
Reactivity
Human
Application
Variant
100 ml
ED7065
In stock
66.00 USD
Variant
100 ml
ED7065
In stock
66.00 USD
Product details
Images
References
IFU download
SDS download
Application
Reactivity
Human
Description
The EXCELLYSE I lysing solution is intended for red blood cell lysis following antibody staining of human peripheral blood leukocytes. The lysing solution is appropriate for use with EXBIO single colour monoclonal antibodies and KOMBITEST reagents and may be used in both lyse/wash and lyse/no wash protocol.
Contents
The content of the vial (100 ml) is sufficient for 500 - 1000 tests. The lysing solution is ready to use.
Storage and handling
Store at 2-25°C.
Exbio licence note
The product is intended for In Vitro Diagnostic Use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

General references:

PH Carter, S Resto-Ruiz, GC Washington, S Ethridge, A Palini, R Vogt, M Waxdal, T Fleisher, PD Noguchi, GE Marti: Flow cytometric analysis of whole blood lysis, three anticoagulants, and five cell preparations, Cytometry 13:68-74 (1992). Wiley-Liss, Inc. 1992.
PubMed
KR Tamul, JL Schmitz, K Kane, and JD Folds: Comparison of the effects of Ficoll-Hypaque separation and whole blood lysis on results of immunophenotypic analysis of blood and bone marrow samples from patients with hematologic malignancies, Clin. Diagn. Lab. Immunol. 1995 May; 2(3): 337–342.
PubMed

Product specific references:

Klocperk A, Bloomfield M, Páráčková Z, Zentsová I, Vrabcová P, Balko J, Meseznikov G, Casas Mendez LF, Grandcourtová A, Šípek J, Tulach M, Zámečník J, Vymazal T and Šedivá A: Complex immunometabolic profiling reveals the activation of cellular immunity and biliary lesions in patients with severe COVID-19. J. Clin. Med. 2020, 9(9), 3000;doi.org/10.3390/jcm9093000
PubMed
Mráz M, Cinkajzlová A, Kloučková J, Lacinová Z, Kratochvílová H, Lipš M, Pořízka M, Kopecký P, Lindner J, Kotulák T, Netuka I, Haluzík M: Dendritic cells in subcutaneous and epicardial adipose tissue of subjects with type 2 diabetes, obesity, and coronary artery disease. Mediators Inflamm. 2019 May 9;2019:5481725.
PubMed
Mráz M, Cinkajzlová A, Kloučková J, Lacinová Z, Kratochvílová H, Lipš M, Pořízka M, Kopecký P, Pierzynová A, Kučera T, Melenovský V, Stříž I, Lindner J, Haluzík M: Coronary artery disease is associated with an increased amount of T lymphocytes in human epicardial adipose tissue. Mediators Inflamm. 2019 Feb 7;2019:4075086.
PubMed
Cinkajzlová A, Lacinová Z, Kloučková J, Kaválková P, Trachta P, Kosák M, Krátký J, Kasalický M, Doležalová K, Mráz M, Haluzík M: An alternatively activated macrophage marker CD163 in severely obese patients: The influence of very low-calorie diet and bariatric surgery. Physiol Res. 2017 Sep 22;66(4):641-652.
PubMed
Novák P, Schmidt R, Kontseková E, Kovacech B, Smolek T, Katina S, Fialová L, Prcina M, Parrak V, Dal-Bianco P, Brunner M, Staffen W, Rainer M, Ondrus M, Ropele S, Smíšek M, Sivák R, Žilka N, Winblad B, Novák M: FUNDAMANT: An interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease. Alzheimers Res Ther. 2018 Oct 24;10(1):108.
PubMed
Faulhaber F, Faulhaber GA, Marcondes N, Procianoy R, Silveira RC: Expression of neutrophil surface markers in icteric neonates before and after phototherapy. Cytometry B Clin Cytom. 2018 Nov;94(6):895-900.
PubMed
Variant
100 ml
ED7065
In stock
66.00 USD
Variant
100 ml
ED7065
In stock
66.00 USD